Please ensure Javascript is enabled for purposes of website accessibility

Is It Too Late to Buy Coronavirus Biotech Stocks?

By Adria Cimino - Updated Mar 20, 2020 at 7:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biotech stocks related to the coronavirus have surged -- but once the outbreak wanes, future gains will depend on the rest of their pipelines.

A handful of biotech companies have been stock-market winners even as the coronavirus outbreak has pushed the market as a whole into bearish territory. The S&P 500 is down 25% since the start of the year, while Moderna (MRNA -4.97%) has gained 47%, Regeneron Pharmaceuticals (REGN 0.61%) rose by 34%, Gilead Sciences (GILD 0.90%) climbed by 24%, and Inovio Pharmaceuticals (INO -4.57%) soared by 96%.

There is no secret to these companies' short-term performance. Each one is working on a treatment or vaccine for coronavirus, the pandemic that so far has resulted in more than 207,000 cases of COVID-19 worldwide. Now investors are wondering: Considering the gains, is it too late to buy shares of these companies?

A vaccine dose is shown against a blurred background.

Image source: Getty Images.

With countries including France and Italy on lockdown, and coronavirus cases increasing in the U.S. and elsewhere, the outbreak isn't over. As long as it continues and biotech companies make progress on their treatment or prevention programs, upside is possible. But that remains a short-term investment strategy.

Revenue gains from coronavirus treatments may be limited, because of the short time frame of pandemics and the ethical question of vaccine pricing. I favor long-term investing, based on each company's entire pipeline. Let's have a closer look at these recent stock-market stars.

Moderna

Moderna is working on a coronavirus vaccine based on its messenger RNA (mRNA) technology, which uses mRNA to instruct the body's cells to make proteins that would prevent disease. Moderna this week said the first participant in its Phase 1 clinical trial for the vaccine has been dosed. The trial, conducted by the National Institutes of Health, will study the safety of the investigational vaccine and the immune responses it generates.

Moderna, on its own, aims to begin a Phase 2 study in a few months. The company has more than 20 candidates in the pipeline for treatment areas including infectious diseases and cancer, but hasn't yet completed Phase 2 studies for any of them. That means we don't yet know whether Moderna's mRNA technology works in humans.

Regeneron

Regeneron this week announced the discovery of hundreds of antibodies that could neutralize coronavirus in its work toward a treatment with the U.S. Department of Health and Human Services. Regeneron said it will select the top two antibodies for its potential treatment and aims to start testing in humans in early summer.

Separately, the company is working with French drugmaker Sanofi (SNY 2.52%), and as part of that project just started a Phase 2/3 trial for rheumatoid arthritis drug Kevzara in New York patients suffering from COVID-19. Beyond work on coronavirus treatments, Regeneron has nearly 30 products in the pipeline in areas such as cardiovascular health and oncology, with six approved drugs. The company has increased annual revenue since 2012.

Gilead

Earlier this month, Gilead began two Phase 3 studies for its investigational antiviral, remdesivir, in coronavirus patients. More recently, the director of the U.S. Centers for Disease Control and Prevention said remdesivir was available via "compassionate use" to coronavirus patients in Washington state, the U.S. epicenter of the outbreak.

Gilead has a full pipeline and nearly 30 products on the market in treatment areas including HIV and cardiovascular health. The company posted a 12% gain last year in sales of HIV products. Analysts predict the HIV drug market will reach $26 billion by 2022 from $20 billion in 2015. And the U.S. Food and Drug Administration is now reviewing filgotinib, Gilead's drug for rheumatoid arthritis, another growing treatment area.

Inovio

Inovio announced recently that it would begin human trials of its coronavirus vaccine next month and aims to present data in the fall. The company's timeline predicts the production of 1 million doses for additional trials or emergency use by the end of the year.

Inovio's investigational products are based on its DNA technology. Here's how it works: Inovio's handheld smart device delivers optimized plasmids into cells via an injection into either the muscle or the skin. These plasmids are circles of double-stranded DNA that have been reorganized by computer sequencing so that the body will produce a specific immune response. Once in the body, these plasmids replicate.

Inovio has seven candidates in the pipeline for multiple tumor types and infectious diseases. This year could be significant for its most advanced product, an immunotherapy for cancers caused by human papillomavirus, as the company expects to report top-line efficacy data from a Phase 3 trial in the fourth quarter.

So what's an investor to do?

I tend to favor biotech companies such as Gilead and Regeneron thanks to the revenue stream they enjoy from products already on the market. But clinical-stage companies like Moderna or Inovio may offer investors just as much opportunity -- if the pipeline is strong enough and the share price hasn't been skyrocketing.

Moderna and Inovio have gained too much too quickly based only on optimism about their coronavirus treatments, so I don't recommend buying them for the long term right now. But once the coronavirus storm passes and the share prices settle, they may be worth a second look.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$661.14 (0.61%) $3.99
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.84 (0.90%) $0.57
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.88 (-4.57%) $0.09
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.25 (-4.97%) $-7.13
Sanofi Stock Quote
Sanofi
SNY
$54.40 (2.52%) $1.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.